Genescience Pharmaceuticals Co. Ltd. has identified phenylalanine hydroxylase (PAH) (R408W mutant) stabilizers reported to be useful for the treatment of phenylketonuria (PKU).
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
The U.S. Patent and Trademark Office (PTO) has proposed to limit the use of administrative challenges to patents when the patent in dispute is already the subject of litigation in district court, a change that many in the life sciences might see as an improvement over the current hyper-litigious environment.
Researchers at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have described oxazole derivatives acting as malate dehydrogenase, cytoplasmic (MDH1) and/or malate dehydrogenase, mitochondrial (MDH2) inhibitors reported to be useful for the treatment of cancer.
Scientists at Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have divulged histone acetyltransferase KAT6A (MOZ; MYST-3) and histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of breast cancer.
Pyrotech (Beijing) Biotechnology Co. Ltd. has identified gasdermin-E (GSDME) inhibitors reported to be useful for the treatment of genetic diseases, cancer, viral infection, age-related macular degeneration, autoimmune diseases, neurological disorders, renal disorders and cancer therapy-associated disorders.
RSS
